Product Pipeline

Clinical-Stage Products Focused on Novel Targets

Oncternal Therapeutics is a clinical-stage oncology company developing potentially first-in-class, novel therapies that target a broad spectrum of cancers with large unmet medical need. By leveraging pathways absent or minimally expressed in normal cells or tissue, we aim to impact cancer cell growth while reducing potential harm to healthy cells. Our current clinical trials include studies in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), breast cancer, and Ewing sarcoma. We are constantly investigating the potential to treat additional malignancies with our product candidates and intend to broaden the indications we are studying. pipeline diagram

We are enrolling patients:

  • With relapsed/refractory mantle cell lymphoma (MCL) for a Phase 1b/2 study of zilovertamab in combination with ibrutinib
  • With chronic lymphocytic leukemia (CLL) for a Phase 2 clinical study of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor 
  • With Ewing sarcoma for a Phase 1 study of ONCT-216, our small-molecule inhibitor of ETS-family transcription factor oncoproteins, in combination with vincristine
Participate in Our Trials